Amneal Pharmaceuticals, Inc.
HealthcareNASDAQ:AMRX · NASDAQ Global Select
-$0.14 today
Vol 2.24M · Avg 1.74M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$3.0B of revenue converted into $122.4M of net income for the selected period. Gross margin is 38.8% and net margin is 4.1%, showing how much revenue survives after costs and taxes. EPS is $0.38, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.0B +8.0% | $2.8B +16.7% | $2.4B +8.2% | $2.2B +5.7% | $2.1B | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $1.9B +6.2% | $1.8B +15.9% | $1.5B +7.7% | $1.4B +7.3% | $1.3B | $725.6M | $804.0M | $882.4M |
| Gross Profit | $1.1B +11.3% | $1.0B +18.1% | $863.9M +9.1% | $791.5M +2.9% | $769.0M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 37.6% +1.1pp | 36.5% +0.4pp | 36.1% +0.3pp | 35.8% -1.0pp | 36.7% | 9.8% | 28.9% | 38.3% |
| Research & Development | $186.2M -2.4% | $190.7M -2.1% | $194.8M -6.7% | $208.7M -0.4% | $209.6M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $526.8M +10.6% | $476.4M +10.9% | $429.7M +7.5% | $399.7M +9.4% | $365.5M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $713.0M -7.5% | $771.1M +16.9% | $659.5M -25.6% | $886.4M +43.8% | $616.3M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $223.6M -5.3% | $236.2M +3.0% | $229.4M -4.5% | $240.2M +2.9% | $233.4M | $374.2M | $1.2B | $631.8M |
| EBITDA | $603.9M +37.3% | $439.8M -12.2% | $500.8M +13.8% | $440.2M +9.8% | $401.1M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 20.0% +4.3pp | 15.7% -5.2pp | 20.9% +1.0pp | 19.9% +0.7pp | 19.2% | 5.6% | 46.3% | 42.0% |
| Operating Income | $423.1M +69.7% | $249.3M +22.0% | $204.4M +315.3% | -$94.9M -162.2% | $152.7M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 14.0% +5.1pp | 8.9% +0.4pp | 8.5% +12.8pp | -4.3% -11.6pp | 7.3% | 16.6% | 24.1% | 22.0% |
| Interest Income | $0 | $0 | $0 -100.0% | $158.4M | $0 | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $241.1M -6.8% | $258.6M +22.8% | $210.6M +33.0% | $158.4M +16.2% | $136.3M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$283.9M +6.7% | -$304.3M -24.4% | -$244.6M -59.7% | -$153.2M -26.2% | -$121.3M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $139.2M +353.0% | -$55.0M -36.6% | -$40.3M +83.8% | -$248.1M -891.1% | $31.4M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 4.6% +6.6pp | -2.0% -0.3pp | -1.7% +9.5pp | -11.2% -12.7pp | 1.5% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $11.3M -40.2% | $18.9M +123.2% | $8.5M +26.9% | $6.7M -40.5% | $11.2M | $1.3B | -$1.6B | $745.2M |
| Net Income | $72.1M +161.6% | -$116.9M -39.2% | -$84.0M +35.4% | -$130.0M -1323.5% | $10.6M | $4.9B | $4.8B | $4.7B |
| Net Margin | 2.4% +6.6pp | -4.2% -0.7pp | -3.5% +2.4pp | -5.9% -6.4pp | 0.5% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $0 +160.5% | -$0 +20.8% | -$0 +44.2% | -$1 -1328.6% | $0 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $0 +157.9% | -$0 +20.8% | -$0 +44.2% | -$1 -1328.6% | $0 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $313.4M +1.4% | $309.0M +76.6% | $175.0M +15.9% | $150.9M +1.4% | $148.9M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $324.8M +5.1% | $309.0M +75.4% | $176.1M +16.7% | $150.9M -0.6% | $151.8M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Lantheus Holdings, Inc.
NASDAQ:LNTH
$6.80B
Mirum Pharmaceuticals, Inc.
NASDAQ:MIRM
$4.99B
Indivior Pharmaceuticals Inc
NASDAQ:INDV
$4.80B
Envista Holdings Corp
NYSE:NVST
$4.00B
Telix Pharmaceuticals Limited
NASDAQ:TLX
$3.24B
Dyne Therapeutics, Inc.
NASDAQ:DYN
$3.01B
Soleno Therapeutics, Inc.
SLNO
$2.76B
Supernus Pharmaceuticals, Inc.
NASDAQ:SUPN
$2.58B
Bausch Health Companies Inc.
NYSE:BHC
$1.89B
Perrigo Company plc
NYSE:PRGO
$1.52B
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does AMRX generate?
Amneal Pharmaceuticals, Inc. (AMRX) reported $3.02B of revenue in fiscal 2025.
Is AMRX profitable?
Amneal Pharmaceuticals, Inc. (AMRX) reported $72.06M of net income, with a net margin of 2.4%.
Explore More
Continue the stock analysis
Jump to another research area for this company.